Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations.
Xing LiWei-Hua ZengYu-Qi ZhouYan-Ying JiWei-Zhan LiLi-Yi ZhangYue-Fei GuoDing Yun FengTian-Tuo ZhangPublished in: OncoTargets and therapy (2019)
NLR was an independent predictor of long-term chemotherapy benefits among non-squamous NSCLC patients without sensitive mutations. Patients with lower NLR were optimal candidates for chemotherapy. Patients with high NLR may receive alternative treatments or be included in clinical trials.
Keyphrases
- locally advanced
- clinical trial
- end stage renal disease
- high grade
- newly diagnosed
- small cell lung cancer
- ejection fraction
- chronic kidney disease
- single cell
- low grade
- prognostic factors
- squamous cell carcinoma
- stem cells
- rectal cancer
- chemotherapy induced
- advanced non small cell lung cancer
- radiation therapy
- cell therapy
- patient reported outcomes
- bone marrow
- open label
- mesenchymal stem cells
- phase ii
- phase iii
- brain metastases